Physician profile
Vishal K Patel
NPI 1083877294
$506,598.64
in general payments reported to CMS, 2019-2025
19 companies · $144K in 2025
The $144K reported for 2025 was more than what 99% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,862 · 2020: $125 · 2021: $23K · 2022: $59K · 2023: $143K · 2024: $135K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $364K · Travel and Lodging: $47K · Food and Beverage: $10K · Education: $215 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $363,551.40 |
| Travel and Lodging | $47,471.43 |
| Food and Beverage | $10,175.88 |
| Education | $214.79 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $296,600.43 | 2019-2025 | Arexvy, Shingrix, Nucala |
| Regeneron Healthcare Solutions, INC. | $127,795.84 | 2021-2025 | Dupixent |
| Genzyme Corporation | $59,775.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $17,798.25 | 2021-2025 | Tezspire |
| Pulmonx Corporation | $1,004.98 | 2019 | |
| Inspire Medical Systems, INC. | $911.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $875.40 | 2025 | |
| Jazz Pharmaceuticals INC. | $831.98 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $150.00 | 2025 | Lumryz |
| W. L. Gore & Associates, INC. | $143.83 | 2021 | |
| Harmony Biosciences LLC | $124.99 | 2020 | |
| Axsome Therapeutics, INC. | $124.74 | 2024 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.44 | 2019 | |
| Covidien Lp | $84.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $57.80 | 2023 | Quviviq |
| Amgen INC. | $49.04 | 2023-2024 | Tezspire |
| Incyte Corporation | $47.31 | 2025 | Opzelura |
| Boston Scientific Corporation | $27.86 | 2025 | Spaceoar System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.